U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312903) titled 'DPTX3186 in Wnt Pathway Activated Solid Tumors' on Dec. 05, 2025.
Brief Summary: This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
Study Start Date: Dec. 16, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: DPTX3186
Once daily (single dose of study drug in the morning in fasted conditions) for 4 consecutive days (4 days on) and 3 days off in a...